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Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting
an estimated 350 million people.1 Current limitations of pharmaceutical treatments
include a delay in therapeutic efficacy of several weeks to months and a lack of efficacy
in approximately a third of the patients with MDD.2,3 Revolutionizing the therapeutic
armamentarium for the treatment of depression, the N-methyl-d-aspartate (NMDA)
receptor antagonist ketamine administered at subanesthetic doses via an intravenous (iv)
route can elicit robust, rapid, and sustained antidepressant effects, even in treatmentresistant patients.4–13 However, the need for iv administration limits the use of ketamine
to an inpatient setting, requiring support services and monitoring.14,15
To minimize the adverse events associated with iv ketamine, including acute dissociative and psychotomimetic effects and cardiovascular changes,7,14–16 recent investigations have attempted alternative routes of administration to elicit rapid antidepressant
effects.17–28 Oral administration is the simplest route to implement. However, due to
its lower bioavailability compared to iv administration, oral ketamine often requires
higher or more frequent dosing.17–19,24,27 Intramuscular and intranasal administration
of ketamine have yielded more promising results with improvement in depression
measures in patients with MDD.20,22 However, injectables are not a preferred administration route for many patients,28 and concerns surrounding inhaler use with regard
to ease of reliable dosing and abuse potential remain.29
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Objective: This study evaluated the effectiveness and safety of subanesthetic doses of ketamine
using an off-label, transmucosal administration route in patients with treatment-resistant
depression.
Methods: A retrospective chart review was conducted to identify patients who met the inclusion criteria for treatment-resistant major depressive disorder. Seventeen such patients who
received subanesthetic doses of ketamine were included. Patient demographics, efficacy (drug
refill, clinician notes), side effects, and concurrent medications were assessed.
Results: Benefit from low-dose transmucosal ketamine was noted in 76% of subjects (average
age 48 years, 88% female), with a dose duration lasting 7–14 days. No notable side effects
were noted. The most common classes of concurrent medications to which ketamine was added
were serotonin–norepinephrine reuptake inhibitors (59%), stimulants (47%), folate replacement
(47%), and benzodiazepines (47%).
Conclusion: Our results provide preliminary evidence of the effectiveness and safety of lowdose transmucosal ketamine in treatment-resistant patients. A controlled, prospective pilot study
is warranted to validate these findings.
Keywords: ketamine, depression, treatment resistance, NMDA receptor, glutamate, mood disorder
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A transmucosal route of administration, in which a
small amount of liquid ketamine (approximately 1 mL) is
absorbed through the oral mucosa rather than swallowed and
thus increases bioavailability (17% oral vs 30% sublingual/
transbuccal),30 may prove more effective. We report herein
a retrospective chart review of 17 patients with treatmentresistant MDD at a psychiatric clinic in Morgantown, WV,
USA who received low-dose ketamine using this alternative
route of administration, which is amenable to outpatient use.
We examined the effectiveness and tolerability of off-label use
of ketamine when administered via the transmucosal route.

Methods
This retrospective chart review was carried out at Chestnut
Ridge Center (Morgantown, WV, USA), a comprehensive
psychiatric treatment facility, and comprised records of
patients with a diagnosis of treatment-resistant MDD who
received clinical services as part of the day hospital program
under the care of Dr Scott Pollard, between January 2011
and September 2013. The diagnosis of MDD was based
on Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) criteria,31 and
treatment resistance was defined as “failure to respond to
two or more trials of antidepressant monotherapy or failure
to respond to four or more trials of different antidepressant
therapies”, including augmentation, combination therapy,
and electroconvulsive therapy.32 Trials with antidepressant
monotherapy were each at least 6 weeks in duration. Augmentation therapies included the addition of an antipsychotic
(eg, aripiprazole), lithium, a stimulant (eg, methylphenidate),
another class of antidepressant (eg, mirtazapine or bupropion),
or l-methylfolate. Typically, patients who were recommended
to the day hospital program, which is synonymous with partial hospitalization, were either recently discharged from the
inpatient unit or were failing outpatient care. Most participants
were long-term patients with significantly persistent mental
illness or patients who function in the community, but were
at risk for inpatient admission or needed help through a turbulent period. Services provided at the day hospital included
medical evaluation and education by an attending psychiatrist
and medical staff in the morning, followed by group therapy
sessions to help increase the patients’ capacity to manage the
symptoms of their illness and improve their quality of life.
Of the patients with MDD who were seen in the day hospital
setting during this period, those who were initiated on the
transmucosal ketamine under off-label usage conditions along
with treatment-as-usual for MDD were identified through
the clinical notes in 18 files. Data were extracted from the
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medical charts of these 18 patients for demographic and illness
variables, concurrent psychotropic medication use, dosing
of ketamine, treatment response, and emergent side effects.
Patients were classified as “responders” or “nonresponders”
on the basis of the clinician’s notes in the medical charts and/
or drug refill history pulled from the West Virginia Board
of Pharmacy Controlled Substance Monitoring Program
(WVBOP CSMP) database. For the drug refill history, we
classified a patient as a responder if he/she filled the ketamine
prescription more than once.
The data from all of the patients in this report have been
de-identified. None of the patients were contacted to obtain
additional clinical or biological data for the purposes of this
manuscript. The Institutional Review Board of West Virginia
University (Morgantown, WV, USA) approved the study.

Results
During the study period, 18 patients who were diagnosed with
treatment-resistant MDD received transmucosal ketamine;
one patient was excluded from the study due to significant
changes in medication regimen after initiation of ketamine
treatment. The demographic, clinical, and treatment variables
of each subject collected from the chart review are detailed
in Table 1. The mean age of the patients was 48 years (range
24–66), and 88% were females. Of the 17 subjects included
in the study, three had a prior history of substance abuse,
though none had active substance abuse disorder at the time
ketamine was initiated. Patients were generally administered
0.5 mg/kg to 1 mg/kg of ketamine from a 50 mg/mL vial of
ketamine. In an effort to reduce side effects, liquid ketamine
was placed on the tongues of the patients and they were
instructed to hold it in their mouths for as long as possible.
Thus, in contrast to standard oral dosing, where the drug
is quickly swallowed, the administration route used in our
patients may best be described as transmucosal. Moreover,
dosing frequency started at every 14 days (based on the iv
ketamine infusion clinical reports)4,9,10 and was reduced to
every 10 or 7 days when it became clear that the patient had
loss of benefit prior to the 14 days.
Out of the 17 subjects who were treated with transmucosal
ketamine, 13 (76%) were classified as responders and four
(24%) as nonresponders. The onset of response was generally noted within 24 hours of taking ketamine. If patients
did not respond within 24 hours, they typically received
no benefit from taking ketamine. Among the responders,
the frequency of dosing was based on the duration of the
antidepressant effect, with seven subjects dosed once every
2 weeks, three once every 10 days, and one once every week.
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NR

NR

NR

NR

2/F/66

3/M/38

4/F/41

5/F/44

7/F/51

NR

NR

NR

1/F/60

6/F/24

History of
substance
abuse

Patient ID
number/
sex/age
(years)
Quetiapinea
Clonazepama
Desvenlafaxinea
l-methylfolatea
Propranolola
Lisdexamfetamine
Clonazepam
Escitalopram
Haloperidol
l-methylfolate
DHA
CoQ10
Tranylcyprominea
Nortriptylinea
Venlafaxine
Methylphenidate
l-methylfolate
Mirtazapine
Pregabalin
Lisdexamfetamine
Propranolol
Aripiprazole
Citalopram
Hydroxyzine
Lithium
Doxazosin
Doxazosin
Hydroxyzine
Desvenlafaxine
l-methylfolate
Fish oil
Venlafaxine
Desvenlafaxine
Clonazepam
Propranolol
Lamotrigine
Hydroxyzine
Fluoxetine
N-acetylcysteine

Concurrent
medications
with KET

Jul 2012

Sep 2012

Aug 2012

Sep 2012

Jun 2012

Dec 2011

Mar 2013

Date KET first
noted in chart

Current:
0.5 mg/kg,
q10d

1st: 0.5 mg/kg,
q2w

Current:
0.5 mg/kg,
q10d

1st: 0.5 mg/kg,
q2w; discon
tinued July
2013

1st: 1 mg/kg,
q2w; discon
tinued July
2012

1st: 0.35 mL
by mouth;
current: 1 mL
by mouth, q1w

NA

Initial (1st)
and most
current KET
dosing*

Patient reported mood is good
since taking ketamine

Patient discharged from day
hospital Jul 2013

Patient reported doing better on
Oct 2012

NA

Ineffective

NA

NA

Efficacy information noted
in chart

Table 1 Demographic and treatment characteristics of the patient sample on transmucosal KET treatment

No side effects noted

No side effects noted

No side effects noted

No side effects noted

No side effects noted

No side effects noted

No side effects noted

Side effects

Jul 2012; Jun 2013
(0.5 mg/kg, q2w)

Sep 2012
(0.67 mL, q2w)

Aug 2012
(0.5 mg/kg, q2w); Jul
2013 (0.5 mg/kg, q2w)

Sep 2012 (0.5 mg/
kg, q2w); Dec 2012
(0.5 mg/kg, q10d)

Jun 2012 (q2w)

Dec 2011 (0.35 mL);
Mar 2012 (q1w); May,
Jun, Jul, Nov 2012
(1 mL, q1w); Mar,
May, Aug 2013 (1 mL,
q1w)

None

KET Rx re/filled
(pharmacy)
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NR

NR

NR

NR

Alcohol
and other
substances

9/F/47

10/F/51

11/F/42

12/F/57

13/F/56

Alcohol

NR

8/F/28

14/M/65

History of
substance
abuse

Patient ID
number/
sex/age
(years)

Table 1 (Continued)

Lisdexamfetamine
Amphetamine/
dextroamphetamine
Duloxetine
Doxepin
l-methylfolate
Amphetamine/
dextroamphetaminea
Trazodonea
Doxepina
Bupropiona
Vilazodone
Trazodone
Aripiprazole
Gabapentin
Buspirone
l-methylfolate
Duloxetine
Propranolol
Omega-3 fatty acids
l-methylfolate
N-acetylcysteine
Hydroxyzine
Risperidone
Clonazepam
Sertraline

Duloxetine
Pregabalin
Lorazepam
Doxazosin
Lisdexamfetamine
Fluoxetine
l-methylfolate
Venlafaxine
Lorazepam

Concurrent
medications
with KET

Dec 2012

Feb 2013

Jan 2012

Aug 2012

Jul 2012

Oct 2012

Feb 2012

Date KET first
noted in chart

NA

1st: 0.5 mg/kg,
q2w; current:
0.5 mg/kg, q2w

NA

1st: 0.5 mg/kg,
q2w; current:
0.5 mg/kg, q2w
1st: 1 mg/kg,
q2w; current:
0.5 mg/kg, q2w
1st: 0.5 mg/kg,
q2w

Discontinued
July 2013

Initial and
most current
KET dosing

Rx filled, but unclear if he took it
because of other health issues (in
and out of the hospital a lot within a
short time span); Patient underwent
10 ECT treatments starting in
Jan 2013 (improved after 6 ECT
treatments; but discontinued after 10
treatments due to adverse memory
effects) and was interested in taking
ketamine as an antidepressant and
willing to restart ECT on Mar 2013

Note: patient is doing well and
mood improved the next day after
ketamine treatment

Note: patient is doing well on
ketamine on Jan 2013

Note that there is continued
improvement on Oct 2012

Patient reported migraines and
mood are better on Aug 2012

Note that ketamine continued
to work well, with strong effects
the following day in Jul 2012; still
benefitting Sep 2012
Patient still on ketamine as of
Oct 2013

Efficacy information noted
in chart

No adverse effects
(specified in chart)

No side effects noted

No side effects noted

Light headaches

No side effects noted

No side effects noted

Side effects

Dec 2012 (as
directed)

Feb, Jul 2013
(0.5 mg/kg, q2w)

Jan 2012, Aug 2012,
Jan 2013 (q2w)

Aug 2012, Feb 2013,
Jun 2013 (0.5 mg/kg,
q2w)

Oct 2012 (0.5 mg/
kg, q2w); Jun 2013
(0.5 mg/kg, q2w)
Jul 2012 (as directed)

None

KET Rx re/filled
(pharmacy)
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Narcotics
18/F/35

NR
17/F/63

NR
16/F/50

Neuropsychiatric Disease and Treatment 2015:11

Notes: Patient 15 was excluded from the study due to changes in medication regimen after initiation of KET treatment and is intentionally excluded in this table. *Where the initial dose is not noted, it was because the information was
not available. aIndicates current psychotropic medications taken at the time of data retrieval (October 2013).
Abbreviations: CoQ10, coenzyme Q10; DHA, docosahexaenoic acid; ECT, electroconvulsive therapy; ER, extended-release; F, female; KET, ketamine; M, male; NA, not available; NR, none reported; q1w, once every week; q2w, once every
2 weeks; q10d, once every 10 days; Rx, prescription.

Yes
1st: 50 mg/mL,
0.6 mL
Jan 2013

Patient reported that ketamine has
helped in augmentation of mood
benefit

None

May 2012, Jan 2013
(q2w)

No side effects
(specified in chart)
except for slight
dizziness for 5 minutes
No side effects noted
1st: 0.5 mg/kg,
q2w; current:
0.5 mg/kg, q2w
May 2012

Note that patient mood was
boosted and is good

Jan 2013
(0.5 mg/kg, q2w)
1st: 0.5 mg/kg,
q2w
Jan 2013

Patient reported she can feel the
difference and can tell when a dose
is due

No side effects noted

Yes

Transmucosal ketamine as a rapid antidepressant

Methylphenidate ER
Doxazosin
Alprazolam
Venlafaxine
Hydroxyzine
Clonazepam
Duloxetine
Galantamine
Quetiapine
Oxcarbazepine
Lorazepam
Divalproex sodium
Citalopram
Lisdexamfetamine
Topiramate
Inositol
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Table 2 Concurrent medications with ketamine
Medication

Subjects taking
the drug (%)

SNRI
Stimulant
Folate replacement
Benzodiazepine
SSRI
Antipsychotic
H1-antihistamine
Beta blocker
Alpha blocker
TCA
Neuropathic pain treatment (pregabalin)

59%
47%
47%
47%
35%
35%
29%
24%
24%
18%
12%

Abbreviations: SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective
serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

The remaining two responders (#8 and #18) did not have
adequate information on maintenance dosing regimens. Of
the 13 responders, two (#2 and #4) were based solely on the
drug refill history (ie, the prescription was filled more than
once but their charts had no note of efficacy). In addition, the
clinical notes for two patients (#8 and #12) explicitly stated
continued benefits with ketamine 6 months or more after the
first ketamine treatment.
Of the four nonresponders (50% females), two had
their prescriptions filled once: one had a note of inefficacy
in the patient chart, and the other subsequently underwent
and responded to ten electroconvulsive therapy treatments
approximately 1 month after the prescription was filled. The
other two nonresponders had no ketamine refill history and
no reports of efficacy in their charts.
Other medications taken concurrently with ketamine
included serotonin–norepinephrine reuptake inhibitors
(n=10), stimulants (n=8), folate replacement (n=8), benzodiazepines (n=8), selective serotonin reuptake inhibitors (n=6),
antipsychotics (n=6), and others (Table 2). Potential drug
interactions or adverse effects are summarized in Table 3.
Overall, no serious adverse events were noted in any of the
subjects initiated on transmucosal ketamine. The two mild
Table 3 Potential drug interactions/adverse effects with
ketamine
Medications

Side effects

Clonazepam, lorazepam, pregabalin, nortriptyline,
hydroxyzine, doxepin, trazodone
Haloperidol, mirtazapine, tranylcypromine
Propranolol, doxazosin
Lisdexamfetamine, amphetamine/
dextroamphetamine

CNS depression
Additive CNS effects
Hypotension
Cardiac effects

Abbreviation: CNS, central nervous system.
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side effects reported were transient light headache (n=1) and
slight dizziness (n=1).
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Discussion
This is an exploratory study in a naturalistic setting of the
potential effectiveness and tolerability of transmucosal
ketamine in 17 patients with treatment-resistant MDD.
The findings in this chart review support previous reports
of effectiveness of low-dose ketamine in rapidly alleviating symptoms of MDD, with effects lasting up to 2 weeks.
Importantly, in contrast to iv ketamine, the administration of
ketamine using the transmucosal route is better tolerated and
has minimal psychiatric side effects. All patients were in a
partial hospitalization program, wherein they were seen frequently and had adequate nursing support for administration/
education and observation with respect to ketamine. There
were no adverse effects that would cause clinical concern for
attempting to address depressive symptoms quickly in an atrisk, treatment-resistant population who otherwise are often
being referred to high levels of care such as acute inpatient
hospitalization.
A similar exploratory study has been conducted using
low-dose sublingual ketamine in refractory unipolar and
bipolar depression, in which patients were instructed to
hold approximately 1 mL liquid ketamine in their mouths
for 5 minutes and then swallow it.23 In that report, ketamine
also produced rapid and relatively sustained antidepressant
effects with only mild and transient light-headedness as a
common side effect (no euphoria, psychotic or dissociative
symptoms).23 Moreover, like the exploratory study using
sublingual ketamine, the nature of our study provided an
opportunity for reviewing treatment response in a “dirty”
population that may be more representative of the treatmentresistant psychiatric patient pool, which is not possible with
randomized controlled trials. Oftentimes, as in our chart
review, the patients have multiple medical and psychiatric
comorbidities, including but not limited to prior substance
use disorders, chronic pain, attention deficit hyperactivity
disorder, borderline personality disorder, and anxiety disorders like posttraumatic stress disorder. With that in mind, it
is reassuring that the addition of low-dose ketamine had no
serious adverse effects, including no drug–drug interactions
or recurrence of substance misuse/abuse. Moreover, though
side effects were not systematically monitored, it is important
to note that these patients were a part of the day hospital
program at the psychiatric center, participating in group
therapy sessions often within 1 hour of taking transmucosal
ketamine and having adequate medical support during their
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stay. None of the patients in our study discontinued using
ketamine because of adverse events, with only mild, transient
side effects noted (headache, dizziness).
This study has many limitations which are inherent to
using a retrospective design. These include the lack of randomization and consistent baseline clinical data. Moreover,
data for each variable were not available in every chart. As
this was not a controlled study and our patient population
had taken a number of medications which may affect the
antidepressant effects and pharmacokinetics of ketamine, we
were also unable to determine whether the positive effects
of treatment were due to ketamine alone or a combination of
ketamine and other therapies. In addition, no standardized
clinical measures were used to evaluate depressive symptoms
and adverse effects, including the monitoring of vital signs.
Tachycardia and increased blood pressure in particular have
been commonly observed following low-dose ketamine
injections14 and should be systematically examined in future
studies with transmucosal ketamine. The reliance on the drug
refill history of a patient as an indicator of therapeutic efficacy
introduces additional concerns that go beyond uncertainties
regarding patient compliance and medication adherence. With
the drug refill history omitted, however, ten of the 17 patients
(ie, 59%) would have been classified as “responders” from
clinical notes of efficacy in the charts, which remains a
sizeable proportion of the treatment-refractory population.
Nevertheless, due to these limitations, a prospective, pilot
study is strongly warranted to validate the efficacy of the
transmucosal route of ketamine as a viable option for eliciting
fast-acting and sustained antidepressant effects, with a side
effect profile suitable for use in outpatients. Whether ketamine
remains as effective if patients were withdrawn from their
routine antidepressants is also of great interest.

Conclusion
This retrospective chart review describes the use of transmucosal ketamine for treatment-resistant depression and
suggests that it may be a safe, tolerable, and effective antidepressant in some depressed patients.
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